Incidence and reasons for late failure after allogeneic haematopoietic cell transplantation following BuCy2 in acute myeloid leukaemia.
The long-term follow-up is presented for 317 patients with acute myeloid leukaemia who underwent human leucocyte antigen-identical sibling marrow transplants between 1984 and 1995 following preparation with busulfan 16 mg/kg and cyclophosphamide 120 mg/kg. Among the 142 (45%) who were alive and leukaemia-free 3 years following transplantation, the leukaemia-free survival at 15 years was 72.8%. The cumulative incidence of late (>3 years beyond transplant) non-relapse mortality at 15 years was 12.9% and of late relapse was 16.5%. None of the variables considered (including age, disease stage, and graft-versus-host disease) were predictive of late failure.
Pant
Shubham
S
Division of Haematology/Oncology, The Ohio State University, Columbus, OH, USA.
Hamadani
Mehdi
M
Dodds
Anthony J
AJ
Szer
Jeffrey
J
Crilley
Pamela A
PA
Stevenson
Dustin
D
Phillips
Gary
G
Elder
Patrick
P
Nivison-Smith
Ian
I
Avalos
Belinda R
BR
Penza
Sam
S
Topolsky
David
D
Sobecks
Ronald
R
Kalaycio
Matt
M
Bolwell
Brian J
BJ
Copelan
Edward A
EA
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016465:Bone Marrow Purging / Q000379:methods; D002066:Busulfan / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D004812:Epidemiologic Methods; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D017211:Treatment Failure; D055815:Young Adult
D003520:Cyclophosphamide; D002066:Busulfan